AMICUS THERAPEUTICS INC

Form 4 June 24, 2015

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB 3235-0287 Number:

Check this box if no longer subject to Section 16.

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

January 31, Expires: 2005

OMB APPROVAL

Form 4 or Form 5 obligations may continue.

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

burden hours per response... 0.5

Estimated average

See Instruction

1(b).

(Last)

(City)

30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of	of Reporting Person
------------------------	---------------------

(First)

(State)

2. Issuer Name and Ticker or Trading

5. Relationship of Reporting Person(s) to Issuer

Castelli Jeff

Symbol AMICUS THERAPEUTICS INC

(Check all applicable)

[FOLD]

(Middle)

(Zip)

3. Date of Earliest Transaction

Director 10% Owner X_ Officer (give title Other (specify below) below)

1 CEDAR BROOK DRIVE

(Month/Day/Year) 06/22/2015

6. Individual or Joint/Group Filing(Check

SVP, Program Management

4. If Amendment, Date Original Filed(Month/Day/Year)

Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting

Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

(3)

(Street)

CRANBURY, NJ 08512

		- I au	16 1 - 14011-1	Derivative	Secui	ines Acquii	cu, Disposeu oi,	or beneficially	y Owneu
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securit onor Dispos (Instr. 3, 4	ed of (Price	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common stock	06/22/2015		M <u>(1)</u>	18,981	A	\$ 13.9417 (2)	43,981	D	
Common stock	06/22/2015		S(1)	18,981	D	\$ 13.9417	25,000	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

Edgar Filing: AMICUS THERAPEUTICS INC - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (right to buy)	\$ 2.52	06/22/2015		M <u>(1)</u>		1,944	06/18/2014	06/18/2023	Common Stock	1,944
Stock Options (right to buy)	\$ 3.53	06/22/2015		M <u>(1)</u>		6,264	01/28/2014	01/28/2023	Common Stock	6,264
Stock Options (right to buy)	\$ 4.16	06/22/2015		M <u>(1)</u>		10,773	11/01/2013	11/16/2019	Common Stock	10,773

Reporting Owners

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

Castelli Jeff

1 CEDAR BROOK DRIVE SVP, Program Management CRANBURY, NJ 08512

Signatures

/s/ Jeff Castelli 06/24/2015

**Signature of Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 17, 2014.
- (2) This price is the weighted average purchase price for the transactions reported on this line. The prices for the transactions reported on this line range from \$13.69 to \$14.10. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate

Reporting Owners 2

Edgar Filing: AMICUS THERAPEUTICS INC - Form 4

price.

This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line (3) range from \$13.69 to \$14.10. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.